BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31423753)

  • 1. Characteristics and outcomes of children with acute myeloid leukemia and Down syndrome who are ineligible for clinical trials due to severe comorbidities.
    Nakashima K; Hasegawa D; Tomizawa D; Miyamura T; Hama A; Iwamoto S; Terui K; Adachi S; Taga T
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27942. PubMed ID: 31423753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.
    Kojima S; Sako M; Kato K; Hosoi G; Sato T; Ohara A; Koike K; Okimoto Y; Nishimura S; Akiyama Y; Yoshikawa T; Ishii E; Okamura J; Yazaki M; Hayashi Y; Eguchi M; Tsukimoto I; Ueda K
    Leukemia; 2000 May; 14(5):786-91. PubMed ID: 10803507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome for Down syndrome patients with hematopoietic disorders.
    Li MJ; Lee NC; Yang YL; Yen HJ; Chang HH; Chien YH; Lu MY; Jou ST; Lin KH; Hwu WL; Lin DT
    J Formos Med Assoc; 2016 Feb; 115(2):94-9. PubMed ID: 26234152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute leukemia associated with Down syndrome: clinical analysis of 21 cases].
    Ran YN; Yu J; Xian Y; Wen XH; Guo YX; Guan XM; Xiao JW
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Mar; 36(3):433-6. PubMed ID: 27063178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.
    Lins MM; Mello MJG; Ribeiro RC; De Camargo B; de Fátima Pessoa Militão de Albuquerque M; Thuler LCS
    Ann Hematol; 2019 Jun; 98(6):1403-1411. PubMed ID: 30915498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
    Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
    Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of patients with Down syndrome and acute leukemia: A retrospective observational study.
    Schmidt MP; Colita A; Ivanov AV; Coriu D; Miron IC
    Medicine (Baltimore); 2021 Oct; 100(40):e27459. PubMed ID: 34622870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland.
    Lerch E; Espeli V; Zucca E; Leoncini L; Scali G; Mora O; Bordoni A; Cavalli F; Ghielmini M
    Tumori; 2009; 95(3):303-10. PubMed ID: 19688968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.
    O'Brien MM; Taub JW; Chang MN; Massey GV; Stine KC; Raimondi SC; Becton D; Ravindranath Y; Dahl GV;
    J Clin Oncol; 2008 Jan; 26(3):414-20. PubMed ID: 18202418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute Leukemia in Down Syndrome Children in Hong Kong: Retrospective Review.
    Lam GK; Leung AW; Ha SY; Luk CW; Li CH; Ling SC; Chiang AK; Li CK
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):102-6. PubMed ID: 26808367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
    Kudo K; Kojima S; Tabuchi K; Yabe H; Tawa A; Imaizumi M; Hanada R; Hamamoto K; Kobayashi R; Morimoto A; Nakayama H; Tsuchida M; Horibe K; Kigasawa H; Tsukimoto I;
    J Clin Oncol; 2007 Dec; 25(34):5442-7. PubMed ID: 18048827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.
    Taga T; Watanabe T; Tomizawa D; Kudo K; Terui K; Moritake H; Kinoshita A; Iwamoto S; Nakayama H; Takahashi H; Shimada A; Taki T; Toki T; Ito E; Goto H; Koh K; Saito AM; Horibe K; Nakahata T; Tawa A; Adachi S
    Pediatr Blood Cancer; 2016 Feb; 63(2):248-54. PubMed ID: 26481183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
    Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
    J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review.
    Gamis AS
    Pediatr Blood Cancer; 2005 Jan; 44(1):13-20. PubMed ID: 15534881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes of myeloid leukemia associated with Down syndrome and de novo acute myeloid leukemia in children: Experience from a single tertiary center in Thailand.
    Songthawee N; Sripornsawan P; Chavananon S; Kittivisuit S; McNeil EB; Chotsampancharoen T
    Pediatr Hematol Oncol; 2024; 41(2):150-162. PubMed ID: 38013232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy.
    Zubizarreta P; Felice MS; Alfaro E; Fraquelli L; Casak S; Quinteros R; Cygler A; Gallego M; Pérez LE; Sackmann-Muriel F
    Leuk Res; 1998 May; 22(5):465-72. PubMed ID: 9652734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891.
    Lange BJ; Kobrinsky N; Barnard DR; Arthur DC; Buckley JD; Howells WB; Gold S; Sanders J; Neudorf S; Smith FO; Woods WG
    Blood; 1998 Jan; 91(2):608-15. PubMed ID: 9427716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
    Taga T; Shimomura Y; Horikoshi Y; Ogawa A; Itoh M; Okada M; Ueyama J; Higa T; Watanabe A; Kanegane H; Iwai A; Saiwakawa Y; Kogawa K; Yamanaka J; Tsurusawa M
    Pediatr Blood Cancer; 2011 Jul; 57(1):36-40. PubMed ID: 21557456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.